Leukemia Trials Need Broader Populations, FDA/ASH Workshop Suggests
Executive Summary
Acute leukemia trials should include a more heterogeneous population, according to panelists at a June 24 workshop sponsored by FDA and the American Society of Hematology
You may also be interested in...
J&J Cautious On Sales Projections Pending FDA, CMS Decisions On ESAs
While awaiting FDA's final safety evaluation and Medicare's final coverage policy on erythropoeisis-stimulating agents, Johnson & Johnson will maintain a conservative stance on sales and earnings for the second half of the year
J&J Cautious On Sales Projections Pending FDA, CMS Decisions On ESAs
While awaiting FDA's final safety evaluation and Medicare's final coverage policy on erythropoeisis-stimulating agents, Johnson & Johnson will maintain a conservative stance on sales and earnings for the second half of the year
Progression-Free Survival Is Meaningful Endpoint For Glioma Trials
Progression free survival assessed at six months should be considered as a meaningful surrogate endpoint in evaluating primary brain tumor clinical trials for accelerated approval, a panel assembled by FDA agreed